Laboratory diagnostics and therapy in thrombosis and hemostasis: From bedside to bench to bedside

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 1, 2009, Pages 3-8

  Lippi, Giuseppe ^a   Favaloro, Emmanuel J ^b   Franchini, Massimo ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; AUTOANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE A; GLUCOSE; HEPARIN; PROTEIN C; PROTEIN S; THROMBIN INHIBITOR; VON WILLEBRAND FACTOR;

BIOLOGICAL RHYTHM; BLOOD ANALYSIS; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL LABORATORY; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EDITORIAL; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; GENE THERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; INSULIN RESISTANCE; INTERNATIONAL NORMALIZED RATIO; LABORATORY DIAGNOSIS; LABORATORY TEST; LUNG EMBOLISM; MEDICAL LITERATURE; MEDICAL PRACTICE; METABOLISM; MONITORING; MORBIDITY; MORTALITY; PATIENT CARE; PERFORMANCE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; THROMBOGENESIS; THROMBOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ANTICOAGULANTS; BLOOD COAGULATION; CIRCADIAN RHYTHM; EVIDENCE-BASED MEDICINE; FACTOR V; FACTOR VII; HEMORRHAGE; HEMOSTASIS; HUMANS; PERIODICALS AS TOPIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THROMBOEMBOLISM; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 63149126760     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1214143     Document Type: Editorial

References (20)

1. Littman BH, Di Mario L, Plebani M, Marincola FM. What's next in translational medicine? Clin Sci (Lond) 2007;112:217-227
2. Lippi G, Plebani M, Guidi GC. The paradox in translational medicine. Clin Chem 2007;53:1553
3. Plebani M. The changing scenario in laboratory medicine and the role of laboratory professionals in translational medicine. Clin Chim Acta 2008;393:23-26
4. Favaloro EJ, Lippi G, Franchini M. Laboratory diagnostics in thrombosis and hemostasis: the past, the present, and the future. Semin Thromb Hemost 2008;34:579-583
5. Tripodi A. The history of phenotypic testing in thrombosis and hemostasis. Semin Thromb Hemost 2008;34:585-592
6. Banfi G, Del Fabbro M. Biological variation in tests of hemostasis. Semin Thromb Hemost 2008;34:635-641
7. Favaloro EJ, Adcock DM. Standardization of the INR: how good is your laboratory's INR and can it be improved? Semin Thromb Hemost 2008;34:593-603
8. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34:58-73
9. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34:39-57
10. Guidi GC, Lippi G. Will "personalized medicine" need personalized laboratory approach? Clin Chim Acta 2009;400:25-29
11. Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin Thromb Hemost 2007;33:759-770
12. Lippi G. Wisdom of theragnostics, other changes. MLO Med Lab Obs 2008;40:6
13. Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost 2008;34:33-38
14. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, doctor! My D-dimer is raised. Ann Med 2008;40:594-605
15. Jennings I, Kitchen DP, Woods TA, Kitchen S, Walker ID. Emerging technologies and quality assurance: the United Kingdom National External Quality Assessment Scheme perspective. Semin Thromb Hemost 2007;33:243-249
16. Favaloro EJ. An update on the vonWillebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007;33:727-744
17. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-733
18. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250-255
19. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008;34:670-682
20. Dawson B, Taylor J, Favaloro EJ. Potential benefits of improved protein intake in older people. Nutr Diet 2008;65:151-156